Phenomenex CEO Appointed to Outward Bound Group
Fasha Mahjoor, founder and CEO of Phenomenex (Torrance, California) was appointed as one of one of Outward Bound Trust's (Cumbria, UK) "25 Strong Chairman's Group" members.
Fasha Mahjoor, founder and CEO of Phenomenex (Torrance, California) was appointed as one of one of Outward Bound Trust’s (Cumbria, UK) “25 Strong Chairman’s Group” members. The newly formed team will meet in early June at Buckingham Palace (London, UK) with Outward Bound’s Chairman, HRH Duke of York, Prince Andrew.
The Outward Bound Trust is a UK charitable organization with local chapters throughout the world. The organization’s goal is to help young men and women realize their potential through outdoor physical challenges and trainings.
Commenting on the appointment, Mahjoor said, “I am honored and particularly enthusiastic. The objective of Outward Bound to successfully develop young people into tomorrow’s leaders is in harmony with many of Phenomenex’s philanthropic endeavors.”
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
